Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05599048 · ClinicalTrials.gov registry record · Phase 1
Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by Robert Bok, MD, PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT05599048: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Robert Bok, MD, PhD.
NCT05599048 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Robert Bok, MD, PhD. The registered enrollment target is 65 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05599048, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Robert Bok, MD, PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center prospective imaging study investigating the utility of hyperpolarized 13C-pyruvate +/-13C,15N-Urea/ metabolic MR imaging. The current protocol will serve as a companion imaging biomarker study paired with standard of care (SOC) therapeutics, as well as investigational therapies that participants may be scheduled to receive outside of this protocol.
Primary Outcome
Signal-to-noise ratios is defined as a MR/spectroscopy parameter, consisting of the HP C13-Pyruvate or Lactate signal (peak) relative to background noise level (baseline) in MRI spectra of the tissue. For the analysis and interpretation of the HP 13C-pyruvate MR imaging data, DICOM software package (SIVIC) will be used to align, display and quantitatively interrogate serial multi-parametric imaging data.
Conditions Studied
Interventions
- DRUG Hyperpolarized 13C-Pyruvate
- PROCEDURE Magnetic Resonance Imaging (MRI)
- DRUG 13C,15N-Urea
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2022-12-15 |
| Est. Completion | 2026-01-31 |
| Phase | Phase 1 |
What NCT05599048 shows while recruiting
NCT05599048 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Hyperpolarized 13C-Pyruvate is the first listed.
NCT05599048 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05599048 about?
NCT05599048 is a clinical study titled "Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors". This is a single center prospective imaging study investigating the utility of hyperpolarized 13C-pyruvate +/-13C,15N-Urea/ metabolic MR imaging. The current protocol will serve as a companion imaging biomarker study paired with standard of care (SOC) therapeutics, as well as investigational therapi...
What is the current status of trial NCT05599048?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2022-12-15. Estimated completion is 2026-01-31.
What conditions does trial NCT05599048 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT05599048?
The interventions under investigation include: Hyperpolarized 13C-Pyruvate (DRUG), Magnetic Resonance Imaging (MRI) (PROCEDURE), 13C,15N-Urea (DRUG).
Who is sponsoring clinical trial NCT05599048?
This trial is sponsored by Robert Bok, MD, PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05599048 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05599048's enrollment target sits among peer trials
65 150th of 189 higher than 39 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI